Guardant Health Introduces Guardant Reveal® Ultra With Enhanced Sensitivity for Minimal Residual Disease Testing

Guardant Health Launches Reveal Ultra, Advancing Ultra-Sensitive MRD Testing for Solid Tumors

Guardant Health, a precision oncology company, has announced the U.S. clinical launch of Guardant Reveal® Ultra, a new molecular residual disease (MRD) testing platform designed to detect residual cancer in patients with solid tumors. The platform uses personalized genomic information to identify cancer signals at extremely low levels, offering physicians another tool to monitor disease and support treatment decisions throughout a patient’s cancer journey.

Built on Guardant Health’s Smart Platform, Guardant Reveal Ultra uses a tumor-informed approach that incorporates patient-specific genomic alterations. This allows the test to look for genetic changes associated with an individual patient’s cancer, helping identify residual disease that may remain after treatment.

The company said the platform has demonstrated detection sensitivity of 1 part per million (ppm) or below across major tumor types. This level of sensitivity is intended to help identify very small amounts of cancer-related genetic material in clinical samples.

Guardant Reveal Ultra has been validated using thousands of clinical samples. Its testing approach incorporates patient-specific alterations drawn from thousands of genomic targets and covers all major variant classes, including structural variants. The platform has also been validated using tissue samples with tumor cellularity as low as 5%, compared with the typical industry requirement of 20% cited by the company.

This lower tissue requirement could allow the test to be used with a broader range of clinical specimens. It may also help address situations in which available tumor tissue contains a relatively small proportion of cancer cells.

According to Guardant Health, Reveal Ultra is designed to bring highly sensitive MRD detection into clinical practice while connecting disease monitoring with other genomic profiling and testing solutions in its precision oncology portfolio.

A New Approach to Detecting Minimal Residual Disease

Minimal residual disease refers to the small amount of cancer that may remain in the body after treatment, even when it cannot be detected through conventional clinical assessments. Detecting this residual disease can be important because very small quantities of cancer cells may remain after surgery or other treatments.

MRD testing uses molecular techniques to identify cancer-associated signals in biological samples. These tests can help physicians monitor patients for signs of residual disease and assess whether cancer-related signals are present during follow-up.

Guardant Reveal Ultra is designed specifically to improve the sensitivity of this type of testing for solid tumors. Its tumor-informed approach uses genomic information from a patient’s tumor to identify alterations associated with that individual’s cancer.

Rather than relying only on a general set of cancer-related markers, the platform incorporates patient-specific genomic alterations. This approach is intended to help distinguish cancer-associated signals from the broader genetic material present in a patient’s sample.

The company reported that Reveal Ultra demonstrated sensitivity of 1 ppm or below across major tumor types. In practical terms, this benchmark refers to the ability to detect a very small cancer-related signal within a much larger amount of background material.

However, sensitivity is only one consideration when evaluating an MRD platform. The ability to maintain performance across different tumor types and real-world clinical samples is also important. Guardant Health says Reveal Ultra was developed to address this challenge through validation across thousands of clinical samples.

Patient-Specific Genomic Targets Support Personalized Testing

One of the central features of Guardant Reveal Ultra is its use of patient-specific genomic alterations. The platform incorporates thousands of genomic targets and includes all major variant classes, including structural variants.

Genomic alterations are changes in DNA that can be associated with cancer development and progression. Different tumors can contain different combinations of these alterations, making personalized genomic analysis an important part of precision oncology.

Structural variants are a category of genomic changes involving larger alterations in the structure or arrangement of DNA. Including these variants expands the range of genomic information that can be considered during testing.

By incorporating multiple types of patient-specific alterations, Guardant Reveal Ultra is designed to create a more comprehensive molecular profile for detecting residual disease.

This approach is particularly relevant in solid tumors, where cancer-associated genomic changes can vary across patients and tumor types. A personalized testing strategy may help physicians monitor the specific molecular characteristics of an individual’s cancer rather than depending entirely on a standardized marker set.

Guardant Health said the platform has been validated across major tumor types, supporting its intended use as part of a broader approach to MRD detection and cancer monitoring.

Lower Tumor Cellular Requirements May Expand Testing Options

Another important feature of Guardant Reveal Ultra is its validation with tissue samples containing as little as 5% tumor cellularity.

Tumor cellularity refers to the proportion of cells in a tissue sample that are cancer cells. A sample with low tumor cellularity contains a relatively small number of cancer cells compared with other cells and tissue components.

This can create challenges for genomic testing because a smaller proportion of tumor cells may make it more difficult to identify cancer-associated genetic alterations.

Guardant Health stated that Reveal Ultra has been validated with samples containing as little as 5% tumor cellularity. The company compared this with a typical industry requirement of 20%.

The lower threshold could make testing possible with a broader range of tissue specimens, including samples that may not meet higher tumor-content requirements.

Access to suitable tissue samples is an important consideration in precision oncology. In some cases, the amount or quality of available tumor tissue may be limited. A platform that can work with specimens containing lower levels of tumor cellularity may provide additional testing flexibility.

The company said this capability is part of its effort to make highly sensitive MRD detection more practical across real clinical settings.

Leadership Highlights the Importance of Reliable Sensitivity

Commenting on the launch, Helmy Eltoukhy, chairman and co-CEO of Guardant Health, described Reveal Ultra as a new development in MRD detection.

Eltoukhy said that detecting cancer at 1 part per million has become an important benchmark, but emphasized that reliable performance across real clinical samples and a broad range of tumor types is equally important.

He explained that Reveal Ultra was developed to address this challenge by bringing high levels of precision into everyday clinical practice. He also highlighted the platform’s potential role in improving the ability to track and manage cancer throughout a patient’s treatment journey.

The comments reflect an important consideration in molecular testing: laboratory sensitivity must be supported by consistent performance across the types of samples encountered in clinical practice.

A test may demonstrate strong analytical performance under specific conditions, but physicians also need confidence that it can deliver useful results across different patient samples and tumor types.

Guardant Health said its validation work involved thousands of clinical samples, supporting the company’s objective of delivering highly sensitive MRD testing across major solid tumor types.

Connecting MRD Detection With Clinical Action

Guardant Reveal Ultra is designed as part of a connected testing experience that can provide physicians with a path from MRD detection to further clinical assessment.

The platform offers physicians the option of a direct path from MRD detection to clinical action through Guardant360® Liquid.

Guardant360 Liquid is part of the company’s comprehensive genomic profiling portfolio. By connecting MRD testing with genomic profiling, Guardant aims to support physicians in using molecular information to guide different stages of cancer management.

The ability to detect residual disease is one part of the broader precision oncology process. Physicians may also need genomic information to understand the molecular characteristics of a patient’s cancer and evaluate potential treatment options.

Guardant Health’s portfolio includes several products designed to support these different needs. Guardant Reveal is intended for tissue-free MRD detection and therapy monitoring, while Guardant360 Liquid and Guardant360® Tissue provide comprehensive genomic profiling.

Reveal Ultra adds another component to this portfolio through its personalized, ultra-sensitive MRD detection capabilities.

Together, these solutions are intended to support physicians in selecting therapies, monitoring treatment response, detecting residual disease, and managing cancer over time.

Guardant Health Expands Its Precision Oncology Portfolio

The launch of Reveal Ultra represents an expansion of Guardant Health’s precision oncology offerings for solid tumors.

Precision oncology uses information about the molecular characteristics of a patient’s cancer to support more individualized approaches to diagnosis, treatment selection, and disease monitoring.

Different testing methods can provide information at different stages of a patient’s cancer journey. Comprehensive genomic profiling can help identify molecular alterations that may be relevant to treatment decisions. MRD testing, meanwhile, focuses on identifying small amounts of cancer-related material that may remain after treatment.

Guardant Health’s portfolio is designed to bring these capabilities together.

Guardant Reveal provides tissue-free MRD detection and therapy monitoring capabilities. Guardant360 Liquid and Guardant360 Tissue offer comprehensive genomic profiling through liquid and tissue-based testing approaches. Reveal Ultra adds a highly sensitive, tumor-informed platform that uses patient-specific genomic alterations to detect residual cancer.

The company said the combination of these solutions completes its precision oncology portfolio, with each product supporting different aspects of cancer care.

For physicians, access to multiple testing approaches may help provide molecular information as patients move through diagnosis, treatment, and follow-up. The goal is to support decisions with information that is relevant to the individual patient’s cancer.

Supporting Cancer Monitoring Throughout the Patient Journey

Cancer management often involves several stages, from identifying the molecular characteristics of a tumor to selecting treatment and monitoring how the disease responds.

After treatment, physicians may also need to assess whether cancer-related signals remain detectable. This is where MRD testing can play a role in supporting ongoing disease monitoring.

Guardant Reveal Ultra is designed to address this need by identifying patient-specific genomic alterations at very low levels. Its reported sensitivity of 1 ppm or below across major tumor types is intended to support the detection of small amounts of residual cancer.

The platform’s tumor-informed approach, broad genomic target coverage, and validation with lower-cellularity tissue samples are key elements of the company’s launch announcement.

Guardant Health has positioned the product as part of a connected precision oncology offering that brings together MRD detection, therapy monitoring, and comprehensive genomic profiling.

The U.S. clinical launch gives physicians access to another testing option within the company’s portfolio. As the use of molecular testing continues to develop in oncology, platforms that combine personalized genomic information with sensitive disease monitoring may become an important part of how cancer is assessed over time.

With Guardant Reveal Ultra, Guardant Health aims to strengthen its role in precision oncology by providing physicians with a new tool for detecting residual disease and supporting cancer management throughout the patient journey.

Source link: https://www.businesswire.com/

Newsletter Updates

Enter your email address below and subscribe to our newsletter